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ABSTRACT
Background. The credibility of sentinel lymph node
(SLN) mapping is becoming increasingly more established
in cervical cancer. We aimed to assess the sensitivity of
SLN biopsy in terms of detection rate and bilateral map-
ping in women with cervical cancer by comparing
technetium-99 radiocolloid (Tc-99m) and blue dye (BD)
versus fluorescence mapping with indocyanine green
(ICG).
Methods. Data of patients with cervical cancer stage 1A2
to 1B1 from 5 European institutions were retrospectively
reviewed. All centers used a laparoscopic approach with
the same intracervical dye injection. Detection rate and
bilateral mapping of ICG were compared, respectively,
with results obtained by standard Tc-99m with BD.
Results. Overall, 76 (53 %) of 144 of women underwent
preoperative SLN mapping with radiotracer and intraop-
erative BD, whereas 68 of (47 %) 144 patients underwent
mapping using intraoperative ICG. The detection rate of
SLN mapping was 96 % and 100 % for Tc-99m with BD
and ICG, respectively. Bilateral mapping was achieved in
98.5 % for ICG and 76.3 % for Tc-99m with BD; this
difference was statistically significant (p\ 0.0001).
Conclusions. The fluorescence SLN mapping with ICG
achieved a significantly higher detection rate and bilateral
mapping compared to standard radiocolloid and BD tech-
nique in women with early stage cervical cancer. Nodal
staging with an intracervical injection of ICG is accurate,
safe, and reproducible in patients with cervical cancer.
Before replacing lymphadenectomy completely, the addi-
tional value of fluorescence SLN mapping on both
perioperative morbidity and survival should be explored
and confirmed by ongoing controlled trials.
Sentinel lymph node (SLN) biopsy has changed the
management of patients with breast cancer and melanoma
and has been integrated into the standard treatment of
selected patients with early stage vulvar cancer.1
Nodal status still represents the most important prog-
nostic factor of surgically staged patients with early stage
cervical cancer. Despite substantial positive evidence
supporting the integration of SLN biopsy into the routine
clinical management of women with an early stage disease,
the accuracy of this procedure still needs to be addressed in
a prospective fashion.
The standard accepted method that has achieved the best
results for SLN biopsy includes the combination of radio-
colloid and blue dye (BD). Literature reports a detection
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rate ranging from 70 to 93 %.2,3 However, recently, great
efforts have been made worldwide to find a more efficient
and reliable tracer.
Indocyanine green (ICG) is a fluorescent dye that has
been used in a variety of applications in medicine since the
1950s, but only recently have its fluorescent properties
been evaluated for SLN mapping of a variety of solid
tumors.4–6 Near-infrared fluorescent imaging with ICG has
been widely investigated and has emerged as a promising
alternative technique for real-time intraoperative SLN
mapping in gynecologic cancer. The higher sensitivity and
bilateral mapping compared to the combined technique or
BD alone, together with the steep learning curve of tradi-
tional laparoscopy, allows surgeons to easily identify the
lymphatic channels and the SLNs, even in an anatomic
region that is unlikely to be explored during routine lym-
phadenectomy.7 Surgical and anesthesia time can be
reduced, which consequently may reduce the costs and
risks associated with surgery. This technique, together with
a minimally invasive laparoscopic approach, appears to be
widely applicable and represents a valid tool compared to
robotic surgery, particularly in those countries and centers
where a robot platform is not available.
The primary objective of this multicenter European
study was to compare the traditional combined technique
using technetium-99 radiocolloid (Tc-99m) and BD and
ICG fluorescent dye in terms of detection rate and bilateral
mapping in patients with early stage cervical cancer




Between 2008 and 2015, women with stage 1A2 to 1B1
cervical cancer were enrolled onto this study from five
European centers (Monza, Berne, Madrid, Varese, and
Rome). All women underwent planned minimally invasive,
radical laparoscopic radical surgery, including SLN map-
ping with bilateral pelvic lymphadenectomy.
The SPIES Full HD Image 1S H3-Z FI camera with the
Karl Storz Near Infrared (NIR/ICG) System (Karl Storz
Endoscopy, Mittelstrasse, Tuttlingen, Germany) was used
by all the participating centers. All patients provided
written informed consent, and the local institutional review
boards approved the study.
Preoperative Lymphoscintigraphy
In 3 centers (Monza, Berne, and Madrid) SLN mapping
was performed using the combined radioisotopic technique
and the BD intraoperative injection until the introduction of
the fluorescence mapping with ICG.
Preoperative LSG was performed using 200 to 300 lCi
of radiolabeled filtered Tc-99m albumin nanocolloid,
injected into the quadrants of the cervix on the day before
surgery. After the injection, a dynamic 10-min planar
anterior LSG (10 frames at 1 min per frame) was carried
out, followed by planar anterior static images, performed
immediately after the dynamic acquisition. When required,
a single-photon emission computed tomography/computed
tomography (SPECT/CT) study was performed 3 h after
the radiotracer injection, with a hybrid system composed of
a dual-head gamma camera with a low-dose X-ray tube
installed in its gantry (Infinia Hawkeye 4, GE Medical
Systems). The overall acquisition time of a SPECT/CT
study was approximately 20 min. Images were analyzed on
a Xeleris workstation (GE Medical Systems).
Intraoperative Tracer Injection
A total of 4 mL of BD (methylene blue 1 %) was
injected. Two milliliters per injection for each side was
administered at the 3 and 9 o’clock positions. The 12
o’clock injection was eliminated in order to avoid staining
the vesicocervicovaginal space of the tumor. The injection
of the BD or ICG was the same for all the involved centers.
The ICG (Pulsion Medical Systems, Feldkirchen, Ger-
many) concentration used was 1.25 mg/mL. For each
patient, a 25 mg vial with ICG powder was diluted in 20
mL of aqueous sterile water. Four to 5 mL of this ICG
solution was injected into the cervix alone, divided into the
3 and 9 o’clock positions. One milliliter of ICG solution
was injected with penetration to a depth of 1 cm into the
stroma, and 1 mL was injected into the submucous layer on
the right and the left of the cervix, usually after the
induction of general anesthesia. In one center (Berne),
patients were injected with 8 to 10 mL of ICG using the
same technique.
Pathology Evaluation
The disease of all women was staged after definitive
histology according to the 2009 classification of the Inter-
national Federation of Gynecology and Obstetrics. An expert
gynecologic oncology pathologist, highly skilled in the
analysis of SLNs, evaluated all surgical samples and SLNs.
All lymph nodes were handled in a standardized manner.8
SLNs with macroscopic metastases were sectioned, and the
SLNs that appeared normal were cut perpendicular to the
long axis. Two adjacent 5 lm sections were cut at each of 2
levels 50 lm apart from each block lacking metastatic car-
cinoma detectable in a routine section stained with
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hematoxylin and eosin (H&E). At each level, one slide was
stained with H&E and the other with immunohistochemistry
using the AE1/AE3 anticytokeratin antibody (Dako,
Glostrup, Denmark). One negative control slide in the total
of five slides per block were stained as well. All other non-
SLNs were only examined by routine H&E.
Micrometastasis was defined as a metastatic deposit
within the SLNs ranging from 0.2 mm to no more than 2
mm in size. Isolated tumor cells (ITC) were defined as
single tumor cells or cluster of malignant epithelial cells
less than 0.2 mm.
Statistical Analysis
Absolute and percentage frequencies were used to
describe categorical items, while median values and ranges
were assessed for continuous variables. Rank sum test and
Fisher’s exact test were used to analyze the differences
between the two groups. Stata 9.0 (StataCorp, College
Station, TX, USA) was used for performing the statistical
analysis. The alpha error was set at 5 % for all
comparisons.
RESULTS
Overall, 144 women with early stage 1A2 to 1B1 cer-
vical cancer from the five European centers underwent
SLN mapping. Seventy-six patients (53 %) underwent
mapping with the standard combination of Tc-99m-positive
BD, whereas the SLN mapping was performed with ICG in
68 patients (47 %) (Fig. 1). As shown in Table 1, the
distribution of pretreatment characteristics such as age,
body mass index, International Federation of Gynecology
and Obstetrics stage, presence of lymphovascular space
invasion, and the count of SLNs removed were balanced
between the groups. There was a higher proportion of G1
tumors in the Tc-99m group. The median number of SLNs
was 2 (range 0–7) in the Tc-99m group and 3 (range 1–15)
in ICG group.
The surgical characteristics of the study groups are
displayed in Table 2. The overall detection rate of SLN
mapping was 96 % and 100 % in the Tc-99m and ICG
groups, respectively. Tumor diameter was\2 cm in 56 %
(43/76) and 51 % (35/68) in the Tc-99m and ICG groups,
respectively. A higher bilateral detection rate was achieved
in the ICG group (98.5 vs. 76.3 %), and this difference was
statistically significant (p\ 0.0001).
While in patients with a tumor diameter less than 2 cm
there was no significant difference between the two groups
in terms of bilateral mapping (p = 0.156), in the case of a
tumor bigger than 2 cm, bilateral mapping was significantly
higher in the ICG group (100 vs. 64 %; p = 0.001).
SLN metastases were discovered in 17 (22 %) of 76
women in the Tc-99m group and in 10 women (14.9 %) in the
ICG group. Among the 3811 SLNs removed in 144 patients,
only 60 presented metastasis (1.6 %). Overall, 41 (9.3 %) of
438 SLNs were positive, including 27 macrometastases (66
%), 12 positive SLNs had micrometastasis (29 %), and two
nodes presented only ITC deposits (5 %). Finally, SLN was
the only positive node in 7 of 10 patients in the ICG group and
in 15 of 17 in the radiocolloid group. Table 3 shows the
number and the type of metastases in per-patient and per-
SLN analyses. There was only one false-negative SLN;
therefore, the sensitivity, negative predictive value, and the
false-negative rate were 96, 99, and 0.04 %, respectively.
DISCUSSION
In 2015, the members of the National Comprehensive
Cancer Network recommended the SLN technique (evi-
dence level 2B) for both early stage cervical and
endometrial cancer.9,10 Furthermore, the panel stressed that
adherence to the algorithm is key to the success of the
technique and that better detection can be achieved in
tumors\2 in diameter.11,12
In that same period, the systematic review of Kadkho-
dayan et al. confirmed that SLN represents an accurate
method for lymph node staging and for identifying small-
volume disease in the SLN (i.e., micrometastasis and ITC)
in patients with cervical cancer.13 Moreover, the lowest
false-negative rate was achieved in the subgroup of women
with tumors\2 cm in diameter and at a lower stage.
In the significant amount of recent literature that focuses
on SLN in cervical tumors, the only multicenter prospec-
tive trial that evaluated the ultrastaging of SLNs was the
SENTICOL (French Ganglion Sentinelle dans le Cancer du
Col) study.14 In this study, 139 women with stage IA1 to
IB1 disease underwent SLN mapping with the standard
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FIG. 1 Plot of SLN mapping by side between groups
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Tc-99m and BD, followed by pelvic lymphadenectomy.
The sensitivity of the whole population was 92 %, but it
reached 100 % in the subgroup of patients with bilateral
SLN mapping (77 %). Those results were confirmed in the
study by Cibula et al., a retrospective multicenter study that
recorded a 91 % sensitivity in SLN ultrastaging, which
improved to 97 % in the case of bilateral SLN mapping,
which resulted in a false-negative rate of 1.3 %.15 One of
the most important aspects of SLN mapping is the detec-
tion of at least one SLN for each hemipelvis. The
adherence to SLN mapping algorithms is important and
allows achieving a low and acceptable false-negative
rate.10 Thus, in the case of failed mapping in a hemipelvis,
a side-specific lymphadenectomy should be performed, and
all or any suspicious peritoneal findings or enlarged lymph
nodes must be evaluated or sampled regardless of the SLN
mapping. Moreover, the recent study by Cibula et al.
highlights the possible impact on survival of low-volume
disease discovered in the SLNs.16 Despite the fact that the
impact of low-volume disease on overall and progression-
free survival is not completely clear, the overall survival of
patients with micrometastasis (7.1 %) was similar to
patients with macrometastasis, and it was statistically sig-
nificant compared to patients with negative SLNs (p \
0.001).
The possibility of avoiding the use of a radioactive agent
such as technetium—which exposes patients to ionizing
radiation and creates many logistical challenges for both
hospital and patients—has prompted the study of new
technologies and dyes such as ICG.
The real-time fluorescence of ICG eliminates the
necessity of a exposing a patient to radioactivity and does
not delay the planned surgical schedule. Therefore, it sig-
nifies that this procedure can also be performed in countries
without access to nuclear medicine.
Fluorescent SLN mapping using ICG was first reported
by Furukawa et al. in 2010 in patients with cervical can-
cer.17 However, Rossi and colleagues had published the
first report on ICG in a minimally invasive platform,
reporting the feasibility of robot-assisted SLN mapping in
20 cases of cervical and endometrial cancer.18 The detec-
tion rate was 85 % (17/20 patients), with a bilateral
TABLE 1 Characteristics of 144 patients
Characteristic Tc-99m ? blue dye (n = 76) ICG (n = 68) p
Age, years, median (range) 47 (26–85) 42 (25–75) 0.263a
BMI, kg/m2, median (range) 24.0 (18–41) 23.7 (16–35) 0.852a
Tumor diameter 0.474b
[2 cm 35 (46.1 %) 30 (44.1 %)
\2 cm 41 (53.9 %) 38 (55.9 %)
pT stage (final pathology) 0.681b
CIS-IA 8 (10.5 %) 10 (14.7 %)
IB1-IIA1c 68 (89.5 %) 58 (85.3 %)
Histology (final pathology) 0.559b
Squamous 55 (72.4 %) 49 (72.1 %)
Adenocarcinoma 20 (26.3 %) 16 (23.5 %)
Clear cells 1 (1.3 %) 3 (4.4 %)
Grade 0.001b
CIS 1 4
G1 13 (17.3 %) 0
G2 34 (45.3 %) 35 (59.3 %)
G3 28 (37.3 %) 24 (40.7 %)
NA 0 5
LVSI 0.392b
Yes 30 (42.3 %) 25 (38.5 %)
No 41 (57.7 %) 40 (61.5 %)
NA 5 3
BMI body mass index, Tc-99m technetium-99 radiocolloid, ICG indocyanine green, NA not available, LVSI lymphovascular space invasion
a Rank sum test
b Fisher’s exact test
c Including 6 cases of IIA1 stage at final pathology with cervical tumor diameter\4 cm
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detection of 60 %. Since this preliminary report, a large
quantity of literature has demonstrated a favorable, reli-
able, and time-efficient method of fluorescent real-time
imaging with ICG for SLN mapping, and interest in its
clinical application is growing. The largest published study
of laparoscopic robot-assisted surgery, that of Jewell et al.,
evaluated the sensitivity of ICG in 227 women whose
disease was surgically staged by applying the SLN algo-
rithm for uterine or cervical cancer.19 Thirty control cases
received a combined intracervical injection of both ICG
and BD. The overall detection rate of the SLN for the
whole group of patients was 95 % (216/227), and the
addition of BD did not improve the bilateral detection of
SLN (ICG 79 vs. BD 77 %). In our study, we observed a
higher detection rate (100 %) and also a higher rate of
bilateral mapping (98.5 %) compared to the latter studies.
However, our study population is less heterogeneous
because it includes only early stage cervical cancer
patients, which represents the most favorable group to
undergo SLN mapping.12
Recent reports have also confirmed these excellent
results for both traditional laparoscopy and robotic
approaches.20–22 Our large, retrospective, multicenter
European study assessed the impact of fluorescent SLN
mapping with ICG in patients with early stage cervical
cancer compared to traditional mapping with radiocolloid
and BD. In our study, real-time fluorescence using ICG
demonstrated a higher detection rate and bilateral mapping
compared to Tc-99m and BD, and the differences are sta-
tistically significant (p\ 0.0001). While in patients with
tumor \2 cm in diameter there was no significant differ-
ence between the 2 groups in terms of bilateral mapping (p
= 0.156), in the case of a tumor [2 cm in size bilateral
mapping was significantly higher in the ICG group (100 vs.
64 %; p = 0.001). Thus, the dimension of a primary cer-
vical lesion seems to affect the nodal mapping performed
by ICG with respect to the traditional method less.
The false-negative rate of our study was 0.04 % because
we recorded only one false-negative case. The woman was
recruited in a center that had just started the experience
with SLN mapping. The learning curve of SLN is well
established, and around 30 cases per surgeon are required
before achieving a good detection rate.23 However, the
evolution of the techniques of mapping, the dedicated
efforts of the surgical team involved, and the introduction
of new agents for mapping, such as fluorescent dye, will
probably shorten the learning curve for the surgeons
approaching to SLN mapping for the first time.
Recent experience underlines the importance of low-
volume nodal metastases detected only by enhanced
pathologic ultrastaging in order to avoid incorrectly
defining a significant number of patients as having node-
negative disease.16,24 Furthermore, later studies have ana-
lyzed the impact on survival of micrometastasis and ITC in
patients with uterine tumors who underwent SLN map-
ping.25,26 Patients with low-volume metastasis received
adjuvant therapy and had improved oncologic outcomes
compared to those with lymph node macrometastasis.
These results are further important reasons for continuing
the evaluation of nodal staging with this promising tech-
nique. Starting from historical anatomic studies, cervical
cancer represents the best anatomic location for intracer-
vical SLN mapping. The in vivo experience faithfully
replicates the studies on cadavers regarding the lymphatic
drainage of the cervix.27 Indeed, the fluorescent dye tech-
nique increases the sensitivity and reliability of this staging
TABLE 2 SLN mapping and lymph node characteristics according to dye used (n = 144)
Characteristic Tc-99m ? blue dye (n = 76) ICG (n = 68) p
Lymph node surgical staging, median (range) 22 (3–82) 22 (2–67) 0.855a
SLN per patient, median (range) 2 (0–7) 3 (1–15) 0.047a
Mapping by side \0.0001b
None 3 (3.9 %) 0
Unilateral 15 (19.7 %) 1 (1.5 %)
Bilateral 58 (76.3 %) 67 (98.5 %)
Bilateral mapping 0.156
Tumor\2 cm 37 (88 %) 34 (97 %) 0.001
Tumor[2 cm 21 (64 %) 33 (100 %)
Patients with positive SLN 17 (22.0 %) 10 (14.9 %) 0.168b
Positive SLN 24/203 (11.8 %) 17/241 (7.1 %) 0.059b
SLN sentinel lymph node, Tc-99m technetium-99 radiocolloid, ITC isolated tumor cell
a Rank sum test
b Fisher’s exact test
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approach, with a bilateral mapping rate of 98.5 % achieved
in the whole study group.
Real-time florescence with ICG represents a new tool
for SLN mapping, particularly in patients with cervical
cancer, and it seems to have several advantages over BD
and radiocolloid tracers. The SPIES system for traditional
laparoscopy allows surgeons to have an excellent high-
definition view of the lymphatic channels and of the SLN
in the operative field, with the aid of a second-generation
fluorescence device.20–22,28 The fluorescent technology is
available for both standard and robotic laparoscopy as well
as for open surgery.29 In addition, the use of the minila-
paroscopic approach can further reduce overall surgical
trauma in selected patients with early stage disease.30 The
lymphatic channels become visible under bright fluorescent
light, which allows the surgeon to follow the lymphatic
channels even in the case of atypical drainage pathways.
The main drawback of our study is its retrospective design.
However, our ICG intracervical injection protocol was
standardized between the centers, as was the lym-
phoscintigraphy protocol in terms of radiocolloid injection
and imaging acquisition.
The use of the ICG eliminates the necessity of radio-
tracer injection and preoperative lymphoscintigraphy in
nuclear medicine, avoiding exposure to radiation for both
patients and healthcare workers. In addition, it can have
less of an unfavorable impact on patients’ quality of life by
facilitating the work flow and operative time of the surgical
operations.
In conclusion, near real-time infrared fluorescent imag-
ing represents an innovative and highly reproducible
technique for SLN mapping in early stage cervical cancer.
ICG mapping resulted in a significantly higher detection
rate and bilateral mapping compared to the standard
combined radiocolloid and BD technique. This new tech-
nique can lead to the reduction of side-specific
lymphadenectomy, required in cases where only unilateral
SLN mapping is achieved, with a consequent reduction in
the duration and additional costs of surgical treatment.
Results of ongoing randomize trials are anxiously awaited
to confirm and assess the validity of these promising
results.
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